HTG2014-Section-Header-publications

Categories

Filter by Topics

478P TA-ness ADCC Gene Alteration adolescents ALK alzheimer's Angiogenesis Anti-TNF Alpha Therapy antiEGFR Apoptosis apoptosis Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells BCL2A1 benign Biofluid Biology of neoplasia Biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Bladder Cancer Blood Brain Breast Cancer Breast milk Burkitt lymphoma cancer genetics Cancer Genomics Cardiovascular Disease Castleman Disease CD3 CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid Chemokines Childhood Atopic Dermatitis chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications cMET Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy end stage kidney disease epidemiology epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma GEIS gene expression Gene Expression gene expression profiling Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors HCC Head and Neck Cancer Heart hepatocellular carcinoma HER-2 HER2 HER2- Histone Deacetylase Inhibitors HLA-E Homing HPV HR+ HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay Ibrutinib ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immunohistochemistry IHC IMMUNOSARC Immunotherapy Inflammation Integrins inverted papilloma ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease Liposarcoma Liquid Biopsy Liver liver tissue Lung Lung cancer Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoma lymphomas machine learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma Mesothelioma MET Method Comparison Microenvironment MicroRNA miRNA miRNA WTA Molecular Characterization Mouse mRNA custom mTOR pathway mTOR signaling multi-omics Multiple Myeloma multiple myeloma Muscle mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic nivolumab Non-alcoholic fatty liver disease non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oncology-Biomarker Oral Cancer Osteoarthritis Osteoclast Ovarian cancer PALLET PALOMA-2 Pancreas Pancreatic Cancer Paralysis Parkinson's Disease Pathogenesis Pathway analysis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PENELOPE-B PFAS PIK3CA mutation Placenta placenta Plasma Platform Comparison PMAIP1 Precision medicine predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate prostate cancer Prostate Cancer prostate genomics Protein Protein Interaction network qNPA qPCR race disparities Radioimmunotherapy RAS Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma sarcoma Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium squamous cell carcinoma Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer tislelizumab TMB tomentosin Toxicity TP53 mutation Transcriptome Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus VEGFR Wound healing Xenograft Tissue Zanubrutinib

2021

Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib

Balasubramanian, S., et al., Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib, British Journal of Haematology,  https://doi.org/10.1111/bjh.17450

View External Link

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021

Download pdf 3.4MB

2020

Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study

Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.

View External Link

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine

Lodhi, N., et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 2020(11):44, 4055-4073. 

Download pdf 3.6MB

2019

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination

Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629

View External Link

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Hicks, S. W., et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Hematologica. 2019 Feb 7; 104(8):1633-1639

Download pdf 1.5MB

Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Ansell, S. M., et al. Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 2019 Jan 8:37(6):481-489

Download pdf 873KB

Page last updated June 23, 2022